Distinguished in Asthma

Laurent Guilleminault

Toulouse, FR 
Distinguished in Asthma
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Laurent Guilleminault practices in Toulouse, France. Mr. Guilleminault is rated as a Distinguished expert by MediFind in the treatment of Asthma. His top areas of expertise are Chronic Cough, Asthma, Anaphylaxis, and Eosinophilic Asthma.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 43 articles and participated in 1 clinical trial in the study of Asthma.

Gender
Male

Locations

Toulouse, 31024, France
Other Locations
Bobigny, France
Bordeaux, France
Tours, 37032, France
UMR 1188 Diabetes Atherothrombosis Therapies Reunion Island Indian Ocean, Reunion Island Indian Ocean Cyclotron Platform, Saint-etienne, France
Saint-pierre-les-bois, 97448, France
Francois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
Chronic Cough and Small Fiber Neuropathy
Chronic Cough and Small Fiber Neuropathy
Enrollment Status: Terminated
Publish Date: October 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
Proteasis Evaluation in COPD
Proteasis Evaluation in COPD
Enrollment Status: Completed
Publish Date: August 26, 2021
View 2 Less Clinical Trials

108 Total Publications

A vaccine targeting human IgE induces long-term protection against anaphylaxis in humanized mice.
A vaccine targeting human IgE induces long-term protection against anaphylaxis in humanized mice.
Journal: Science translational medicine
Published: December 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guilleminault's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile